15 Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.

16 Antiviral activity of extracted fraction from camel urine against corona and influenza a (H1N1) viruses

17 Hormonal Regulation of Physiology, Innate Immunity and Antibody Response to H1N1 Influenza Virus Infection During Pregnancy

18 [The Effects and Mechanisms of Dihydroartemisinin on Influenza A Virus H1N1 Induces TNF-α and IL-6 Expression in Bronchial Epithelial Cells].

19 Cloning, expression, and purification of the recombinant hemagglutinin of human influenza virus H1N1 in the eukaryotic insect cells using baculovirus vector

20 Virus Detection and Duration of Illness Among Patients With 2009 Pandemic Influenza A (H1N1) Virus Infection in Texas

21 Delayed Clearance of Viral Load and Marked Cytokine Activation in Severe Cases of Pandemic H1N1 2009 Influenza Virus Infection

22 Comparison of Patients Hospitalized With Influenza A Subtypes H7N9, H5N1, and 2009 Pandemic H1N1

23 Pre-existing Antineuraminidase Antibodies Are Associated With Shortened Duration of Influenza A(H1N1)pdm Virus Shedding and Illness in Naturally Infected Adults

24 Household Transmission of 2009 Pandemic Influenza A (H1N1) and Nonpharmaceutical Interventions among Households of High School Students in San Antonio, Texas

25 Effect of Clinical and Virological Parameters on the Level of Neutralizing Antibody against Pandemic Influenza A Virus H1N1 2009

26 Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection

27 managment of infectious disease outbreak: lessons learnt from the h1n1 outbreak

28 molecular characterization of severe and mild cases of influenza a (h1n1) 2009 strain from argentina caracterización molecular de cepas de influenza a (h1n1) 2009 de casos leves y graves de la argentina

29 mutation analysis of the neuraminidase gene of influenza a(h1n1)pdm09 in tunisia between 2009 and 2017 seasons

30 the impact of altitude on hospitalization and hospital mortality from pandemic 2009 influenza a (h1n1) virus pneumonia in mexico el impacto de la altitud en las tasas de hospitalización y mortalidad por el virus de la influenza a (h1n1) pandémico en méxico

31 reacciones adversas a la vacuna contra influenza a (h1n1) en trabajadores de salud de una institución pública peruana

32 perfil epidemiológico de la mortalidad por influenza humana a (h1n1) en méxico epidemiological profile of mortality due to human influenza a (h1n1) in mexico

33 assessment of epicutaneous testing of a monovalent influenza a (h1n1) 2009 vaccine in egg allergic patients

34 risco de uma pandemia de influenza pelo vírus a (h1n1) the risk of a pandemic with the influenza a (h1n1) virus

35 a hypothesis: supplementation with mushroom-derived active compound modulates immunity and increases survival in response to influenza virus (h1n1) infection

36 risk factors associated with death among influenza a (h1n1) patients, tamil nadu, india, 2010

37 awareness and acceptance of h1n1 vaccination among physicians: experience of 2017 vaccination campaign

38 combined interventions for mitigation of an influenza a (h1n1) 2009 outbreak in a physical training camp in beijing, china

39 experimental adaptation of an influenza h5ha strain confers respiratory droplet transmission to reassortant h5h/h1n1 virus strain in ferrets

40 treatment of immunocompromised, critically ill patients with influenza a h1n1 infection with a combination of oseltamivir, amantadine, and zanamivir

41 pandemic h1n1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem

42 perspectives of pulmonologists on the 2009-2010 h1n1 vaccination effort

43 influenza a h1n1 de origen porcino: métodos diagnósticos

44 h1n1 infection and acute respiratory failure: can we give non-invasive ventilation a chance?

45 postvaccination influenza 2009 h1n1 respiratory failure requiring extracorporeal membrane oxygenation

46 intravenous ketamine for refractory bronchospasm precipitated by h1n1 infection

47 polymyositis following pandemic influenza a (h1n1) and 2009-10 seasonal trivalent vaccines

48 ns segment of a 1918 influenza a virus-descendent enhances replication of h1n1pdm09 and virus-induced cellular immune response in mammalian and avian systems

49 guía de estudio y manejo de casos y sus contactos para enfermedad similar a influenza, incluyendo el diagnóstico, manejo clínico y terapéutico adaptación a influenza por virus nuevo a h1n1 guide of study and managing of cases and contacts for similar disease to influenza, including the diagnosis, clinical and therapeutic managing adjustment to influenza for new virus a h1n1

50 the relationship between pulmonary hrct findings and peripheral blood immunological parameters in adults with h1n1 influenza

51 four narcolepsy cases after h1n1 infection or vaccination

52 san wu huangqin decoction, a chinese herbal formula, inhibits influenza a/pr/8/34 (h1n1) virus infection in vitro and in vivo

53 pandemia de influenza a por nuevo virus h1n1

54 prevalence of influenza a (h1n1) seropositivity in unvaccinated healthcare workers in scotland at the height of the global pandemic

55 knowledge, attitudes, and practices regarding pandemic h1n1 influenza among medical and dental residents and fellowships in shiraz, iran

56 an outbreak of influenza among physicians during the first wave of mexico city's 2009 h1n1 epidemic

57 de las vacunas a la gripe a (h1n1): ¿precaución y prevención sin límites?

58 henoch-schönlein purpura following influenza a h1n1 vaccination

59 severe 2009 h1n1 infection in early pregnancy

60 transverse myelitis with brown-sèquard syndrome after h1n1 immunization

61 Viral load in patients infected with pandemic H1N1 2009 influenza A virus

62 Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies

63 Geographic dependence, surveillance, and origins of the 2009 influenza A (H1N1) virus

64 Serial Intervals and the Temporal Distribution of Secondary Infections within Households of 2009 Pandemic Influenza A (H1N1): Implications for Influenza Control Recommendations

65 Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses

66 Coinfection by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza A(H1N1)pdm09 Virus Enhances the Severity of Pneumonia in Golden Syrian Hamsters

67 Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide

68 Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009

69 Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets

70 Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study

71 A Population-Based Study of Neurologic Manifestations of Severe Influenza A(H1N1)pdm09 in California

72 Diagnosis of 2009 Pandemic Influenza A (pH1N1) and Seasonal Influenza Using Rapid Influenza Antigen Tests, San Antonio, Texas, April–June 2009

73 Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China

74 Confirmation of the first Hong Kong case of human infection by novel swine origin influenza A (H1N1) virus diagnosed using ultrarapid, real-time reverse transcriptase PCR

75 Molecular modeling studies demonstrate key mutations that could affect the ligand recognition by influenza AH1N1 neuraminidase

Keyword Connections

Journals

Research Groups

Bibliographies